Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Therapy Directory

Capecitabine clinical trials

Directory of U.S. ClinicalTrials.gov public records that list Capecitabine as a study intervention. Browse Capecitabine recruiting trials, filter by phase, sponsor, or location, and open the official ClinicalTrials.gov study record for each result.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 2:33 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
760
Shown on this page
12
Current sort
Recently updated
Therapy scope
Capecitabine
Additional filters apply within this therapy.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this therapy

These controls apply only within Capecitabine. Default order is Recently updated. Add condition, location, sponsor, or recruitment status to narrow this therapy page further.

Reset therapy filters
Clear filters
Showing 349–360 of 760 matching trials for Capecitabine.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search
Withdrawn Phase 1Phase 2 Interventional

QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) Vaccine

NCT03563170
View directory record Official record
Conditions
Hepatocellular Carcinoma Non-resectable, Hepatocellular Carcinoma Recurrent
Interventions
ETBX-011, GI-4000, haNK for infusion, avelumab, Capecitabine, Cyclophosphamide, 5-Fluorouracil, Leucovorin, nab-Paclitaxel, Sorafenib, SBRT, Aldoxorubicin hydrochloride, ETBX-051, ETBX-061, GI-6207, GI-6301, Cetuximab, N-803
Biological · Drug · Procedure
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
El Segundo, California
Source: ClinicalTrials.gov public record
Updated Mar 18, 2021 · Synced Oct 29, 2026, 2:33 AM EDT
Terminated Not applicable Interventional Results available

Combination Chemotherapy and Cetuximab or Bevacizumab in Treating Patients With Metastatic Colorectal Cancer

NCT01280643
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
fluorouracil, leucovorin calcium, oxaliplatin, irinotecan hydrochloride, bevacizumab, cetuximab, capecitabine, mutation analysis, gene expression analysis, laboratory biomarker analysis, immunohistochemistry staining method, nucleic acid sequencing, protein expression analysis, polymerase chain reaction, DNA analysis
Drug · Biological · Genetic + 1 more
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 15, 2021 · Synced Oct 29, 2026, 2:33 AM EDT
Terminated Phase 1 Interventional Results available

BrUOG 302:BYL719, Capecitabine and Radiation for Rectal Cancer: A Brown University Oncology Research Group Study

NCT02550743
View directory record Official record
Conditions
Rectal Cancer
Interventions
BYL719, Capecitabine, Radiation
Drug · Radiation
Lead sponsor
howard safran
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Mar 12, 2021 · Synced Oct 29, 2026, 2:33 AM EDT
Completed Phase 2 Interventional Results available

A Phase II Study of Everolimus in Combination With Exemestane Versus Everolimus Alone Versus Capecitabine in Advance Breast Cancer.

NCT01783444
View directory record Official record
Conditions
Breast Cancer
Interventions
Capecitabine, Exemestane, Everolimus
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
309 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
19
States / cities
Los Angeles, California • San Diego, California • Fort Myers, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2021 · Synced Oct 29, 2026, 2:33 AM EDT
Completed Phase 2 Interventional Results available

Non-Operative Radiation Management of Adenocarcinoma of the Lower Rectum

NCT02641691
View directory record Official record
Conditions
Cancer of Rectum, Cancer of the Rectum, Neoplasm, Rectum, Rectal Cancer, Rectum Cancer, Rectum Neoplasms, Adenocarcinoma of the Rectum
Interventions
Radiation, Oxaliplatin, Leucovorin, Fluorouracil
Radiation · Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 18, 2021 · Synced Oct 29, 2026, 2:33 AM EDT
Withdrawn Phase 2Phase 3 Interventional

Capecitabine and Paclitaxel (Albumin-Stabilized Nanoparticle Formulation) in Treating Women Undergoing Surgery for Stage II or Stage III Breast Cancer

NCT00397761
View directory record Official record
Conditions
Breast Cancer
Interventions
capecitabine, paclitaxel albumin-stabilized nanoparticle formulation, neoadjuvant therapy
Drug · Procedure
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
18 Years to 120 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Feb 17, 2021 · Synced Oct 29, 2026, 2:33 AM EDT
No Longer Available No phase listed Expanded access

Open Label Continuation Study of TRC105 for Patients Who Have Completed a Prior TRC105 Trial

NCT02354612
View directory record Official record
Conditions
Solid Tumors
Interventions
TRC105, Bevacizumab, Axitinib, Pazopanib, Capecitabine
Drug
Lead sponsor
Tracon Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Feb 15, 2021 · Synced Oct 29, 2026, 2:33 AM EDT
Completed Phase 1 Interventional

Intermittent High-Dose Lapatinib in Tandem With Capecitabine for HER2 Overexpressed/Amplified Metastatic Breast Cancer With Central Nervous System (CNS) Metastases

NCT02650752
View directory record Official record
Conditions
Metastatic Breast Cancer, Central Nervous System (CNS) Metastases
Interventions
Lapatinib in Tandem With Capecitabine
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
9
States / cities
Ann Arbor, Michigan • Basking Ridge, New Jersey • Middletown, New Jersey + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2021 · Synced Oct 29, 2026, 2:33 AM EDT
Completed Phase 3 Interventional Results available

A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastroesophageal Junction or Gastric Cancer

NCT01774786
View directory record Official record
Conditions
Gastric Cancer
Interventions
5-Fluorouracil, Capecitabine, Cisplatin, Pertuzumab, Placebo, Trastuzumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
780 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
10
States / cities
Fort Myers, Florida • Chicago, Illinois • Goshen, Indiana + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2020 · Synced Oct 29, 2026, 2:33 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Neoadjuvant Chemoradiotherapy With CRLX-101 and Capecitabine for Rectal Cancer

NCT02010567
View directory record Official record
Conditions
Rectal Cancer
Interventions
CRLX101, Capecitabine, Radiotherapy, Surgery
Drug · Radiation · Procedure
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
6
States / cities
Denver, Colorado • Indianapolis, Indiana • Chapel Hill, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2020 · Synced Oct 29, 2026, 2:33 AM EDT
Completed Phase 3 Interventional Results available

Novel Epothilone Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer

NCT00080301
View directory record Official record
Conditions
Breast Cancer, Metastases
Interventions
Ixabepilone + Capecitabine, Capecitabine
Drug
Lead sponsor
R-Pharm
Industry
Eligibility
18 Years and older · Female only
Enrollment
752 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
32
States / cities
Little Rock, Arkansas • San Francisco, California • Vallejo, California + 29 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2020 · Synced Oct 29, 2026, 2:33 AM EDT
Completed Phase 3 Interventional Results available

Epothilone (Ixabepilone) Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer

NCT00082433
View directory record Official record
Conditions
Cancer, Breast Cancer
Interventions
Ixabepilone + Capecitabine, Capecitabine
Drug
Lead sponsor
R-Pharm
Industry
Eligibility
18 Years and older · Female only
Enrollment
1,221 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
34
States / cities
Tucson, Arizona • Beverly Hills, California • Corona, California + 31 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2020 · Synced Oct 29, 2026, 2:33 AM EDT

About this Capecitabine clinical trials directory page

What this page lists
U.S. ClinicalTrials.gov public records that list Capecitabine as a study intervention, including recruiting, not yet recruiting, and active not recruiting trials.
How to narrow results
Use the filters above to scope by condition, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Capecitabine.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Related: all therapy pages, browse by condition, browse by U.S. city, browse by sponsor, or open the full search for Capecitabine.